Genetic Polymorphism of Cytokines as a Predictor of Phenotypic Development of Chronic Pain Syndrome in Cancer Patients

Olga P. Bobrova,¹ʼ²; Natalia A. Shnayder, PhD, ScD*¹; Marina M. Petrova, PhD,ScD¹; Oksana A. Gavrilyuk, PhD¹

¹V.F. Voyno-Yasenetsky Krasnoyarsk State Medical University; ² Krasnoyarsk Regional Clinical Oncology Dispensary named after A.I. Kryzhanovsky. Krasnoyarsk, the Russian Federation.

*Corresponding author:  Prof. Natalia A. Shnayder, PhD, ScD; Head of the Neurological Center of Epileptology, Neurogenetics and Brain Research of the University Clinic of V.F. Voino-Yasenetsky Krasnoyarsk State Medical University.  Krasnoyarsk, the Russian Federation.  E-mail:

Published: December 15, 2017.  doi: 10.21103/Article7(4)_RA1


The authors present a literature review using materials provided in the following databases:  “MedLine”, “PubMed”, “Wiley Online Library”, “Web of Science”, “Oxford University Press”, “SAGE Premier”, dated 1995–2016. The paper describes the results of current international studies on the role of cytokine genes polymorphisms in the genesis of chronic cancer pain. We emphasize the role of inter-individual differences based on genetic polymorphism of cytokines and their receptors in personalized anesthetic care and accompanying therapy in oncology..

chronic pain ● oncology ● analgesic therapy ● pharmacogenetics ● nociception ● cytokine receptors
  1. Mikaelyan MF, Adzhienko VL. [Conceptions and problems of chronic pain syndrome treatment at the present stage]. Lekarstvennii Vestnik. 2016; 2(62): 28-30. [Article in Russian].

  2. Yakhno NN, Kukushkin ML, editors. Pain (practical guide for physicians). Moscow: Izdatel'stvo RAMN; 2012. 512 p. [in Russian].

  3. Balashova TV, Andreeva NA, Mnatsakyan LA, Kotelnikova AG, Dolgunov AM. [Present-day ideas on pathogenesis of pain]. Pacific Medical Journal. 2012; 3:13 - 16. [Article in Russian].

  4. Wang XB, Li YS, Li J, Han Y, Liu ZD. Interleukin-8 -251A/T gene polymorphism and lung cancer susceptibility: a meta-analysis. J Cell Mol Med. 2015; 19(6):1218-22. doi:10.1111/jcmm.12466

  5. Schmidt BL, Hamamoto D T, Simone D A, Wilcox GL.  Mechanisms of cancer pain. Mol Interv. 2010; 10(3):164-78. doi: 10.1124/mi.10.3.7.

  6. Yoneda T, Hata K, Nakanishi M, Nagae M, Nagayama T, Wakabayashi H, et al. Involvement of acidic microenvironment in the pathophysiology of cancer-associated bone pain. Bone. 2011; 48(1):100-5. doi: 10.1016/j.bone.2010.07.009.

  7. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010; 140(6):883-99. doi: 10.1016/j.cell.2010.01.025.

  8. Matveeva LV, Mosina LM. [The role of interleukin-1 and associated cytokines in gastric carcinogenesis]. Vestn Ross Akad Med Nauk. 2012;67(11):59-65. doi:10.15690/vramn.v67i11.473. [Article in Russian].

  9. Branford R, Droney J, Ross JR. Opioid genetics: the key to personalized pain control? Clin Genet. 2012; 82(4):301–10. doi: 10.1111/j.1399-0004.2012.01923.x

  10. Neeb L, Hellen P, Boehnke C, Hoffmann J, Schuh-Hofer S, Dirnagl U, Reuter U. IL-1beta stimulates COX-2 dependent PGE2 synthesis and CGRP release in rat trigeminal ganglia cells. PLoS One. 2011;6(3): e17360. doi: 10.1371/journal.pone.0017360.

  11. Hirata H, Tetsumoto S, Kijima T, Kida H, Kumagai T, Takahashi R, et al. Favorable responses to tocilizumab in two patients with cancer - related cachexia. J Pain Symptom Manage. 2013;46(2):e9–e13. doi: 10.1016/j.jpainsymman.2013.01.009

  12. Wang XM, Lehky TJ, Brell JM, Dorsey SG. Discovering cytokines as targets for chemotherapy-induced painful peripheral neuropathy. Cytokine. 2012;59(1):3-9. doi: 10.1016/j.cyto.2012.03.027. 

  13. Guo G, Gao F. CXCR3: latest evidence for the involvement of chemokine signaling in bone cancer pain. Exp Neurol. 2015;265:176-9.doi:10.1016/j.expneurol.2015.02.003.

  14. Vendrell I, Macedo I, Alho M, Dionísio MR, Costa L. Treatment of cancer pain by targeting cytokines. Mediators Inflamm. 2015; 2015:984570. doi: 10.1155/2015/984570.

  15. Jaggi AS, Singh N. Mechanisms in cancer-chemotherapeutic drugs-induced peripheral neuropathy. Toxicology. 2012;291(1-3):1-9. doi: 10.1016/j.tox.2011.10.019.

  16. Saijo Y, Tanaka M, Miki M, Usui K, Suzuki T, Maemondo M, et al. Proinflammatory cytokine IL-1 beta promotes tumor growth of Lewis lung carcinoma by induction of angiogenic factors: in vivo analysis of tumor-stromal interaction. J Immunol. 2002;169(1):469–75.

  17. Kiguchi N, Kobayashi Y, Kishioka S. Chemokines and cytokines in neuroinflammation leading to neuropathic pain. Curr Opin Pharmacol. 2012;12(1):55–61. doi: 10.1016/j.coph.2011.10.007.

  18. Guan XH, Fu QC, Shi D, Bu HL, Song ZP, Xiong BR, et al.  Activation of spinal chemokine receptor CXCR3 mediates bone cancer pain through an Akt-ERK crosstalk pathway in rats. Exp Neurol. 2015; 263:39-49. doi: 10.1016/j.expneurol.2014.09.019.

  19. Doong SH, Dhruva A, Dunn LB, West C, Paul SM, Cooper BA, et al.  Associations between cytokine genes and a symptom cluster of pain, fatigue, sleep disturbance, and depression in patients prior to breast cancer surgery. Biol Res Nurs. 2015;17(3):237-47. doi: 10.1177/1099800414550394.

  20. Reyes-Gibby CC, Shete S, Yennurajalingam S, Frazier M, Bruera E, Kurzrock R, et al. Genetic and nongenetic covariates of pain severity in patients with adenocarcinoma of the pancreas: assessing the influence of cytokine genes. J Pain Symptom Manage. 2009;38(6):894–902. doi: 10.1016/j.jpainsymman.2009.04.019

  21. Luo M, Yang Y, Luo D, Liu L, Zhang Y, Xiao F, et al. Tumor necrosis factor-alpha promoter polymorphism 308 G/A is not significantly associated with esophageal cancer risk: a meta-analysis. Oncotarget. 2016;7(48):79901-79913. doi: 10.18632/oncotarget.13093.

  22. Bandil K, Singhal P, Sharma U, Hussain S, Basu S, Parashari A, et al. Impacts of TNF-LTA SNPs/haplotypes and lifestyle factors on oral carcinoma in an Indian population. Mol Diagn Ther. 2016;20(5):469-80. doi: 10.1007/s40291-016-0215-2.

  23. Zhao H, Zhang HW, Zhang T, Gu XM. Retraction RETRACTION of “Tumor necrosis factor alpha gene -308G>A polymorphism association with the risk of esophageal cancer in a Han Chinese population” by H.Zhao, H.W. Zhang, T.Zhang and X.M. Gu – Genet. Mol. Res. 15(2):gmr.15025866 DOI: Genet Mol Res. 2016; 15(4). doi: 10.4238/gmr.150458661.

  24. Reyes-Gibby CC, Spitz MR, Yennurajalingam S, Swartz M, Gu J, Wu X, et al. Role of inflammation gene polymorphisms on pain severity in lung cancer patients. Cancer Epidemiol Biomarkers Prev. 2009;18(10):2636–42. doi: 10.1158/1055-9965.EPI-09-0426

  25. Sun Q, Guo X, Wang Q, Zhao F. The association of TNF-308 (G/A) gene polymorphisms and hepatocellular carcinoma risk: a meta-analysis. Chin J Cancer Res. 2016;28(5):536-542.

  26. Rausch SM, Gonzalez BD, Clark MM, Patten C, Felten S, Liu H, et al. SNPs in PTGS2 and LTA predict pain and quality of life in long term lung cancer survivors. Lung Cancer. 2012; 77(1):217-23. doi: 10.1016/j.lungcan.2012.02.017.

  27. Wang Z, Liu Y, Yang L, Yin S, Zang R, Yang G. The polymorphism interleukin-8 -251A/T is associated with a significantly increased risk of cancers from a meta-analysis. Tumour Biol. 2014;35(7):7115-23. doi: 10.1007/s13277-014-1881-5.

  28. Baune BT, Dannlowski U, Domschke K, Janssen DG, Jordan MA, Ohrmann P, et al. The interleukin 1 beta (IL1B) gene is associated with failure to achieve remission and impaired emotion processing in major depression. Biol Psychiatry. 2010;67(6):543–9. doi: 10.1016/j.biopsych.2009.11.004

  29. Reyes-Gibby CC, Spitz M, Wu X, Merriman K, Etzel C, Bruera E, et al. Cytokine genes and pain severity in lung cancer: exploring the influence of TNF-alpha-308 G/A IL6-174G/C and IL8-251T/A. Cancer Epidemiol Biomarkers Prev. 2007; 16(12):2745–2751. doi:10.1158/1055-9965.epi-07-0651

  30. Reyes-Gibby CC, Spitz MR,Yennurajalingam S, Swartz M, Gu J, Wu X, et al. Role of inflammation gene polymorphisms on pain severity in lung cancer patients. Cancer Epidemiol Biomarkers Prev. 2009; 18(10):2636-42. doi: 10.1158/1055-9965.EPI-09-0426.

  31. Müerköster S, Wegehenkel K, Arlt A, Witt M, Sipos B, Kruse ML, et al. Tumor stroma interactions induce chemoresistance in pancreatic ductal carcinoma cells involving increased secretion and paracrine effects of nitric oxide and interleukin-1beta. Cancer Res. 2004;64(4):1331–7.

  32. Gan WY, Li HM, Zhang YG, Li CM, Wang Y. Association between IL18-607C/A and -137G/C polymorphisms and susceptibility to non-small cell lung cancer in a Chinese population. Genet Mol Res. 2016;15(4). doi: 10.4238/gmr15048822.

  33. Zhao K, Xu J, Tian H. RETRACTION of “Correlation analysis between an IL-6 genetic polymorphism and non-small cell lung cancer prognosis”,by Zhao K, Xu J, Tian H published in Genetics and Molecular Research 15 (1): 15017021 (2016) DOI: 10.4238/gmr.15017021. Genet Mol Res. 2016; 15(4). doi: 10.4238/gmr.15017021.

  34. Quesada JR, Talpaz M, Rios A, Kurzrock R, Gutterman JU. Clinical toxicity of interferons in cancer patients: a review. J Clin Oncol. 2015; 4(20):234-43. doi:10.1200/JCO.1986.4.2.234

  35. Von Ah DM, Kang DH, Carpenter JS. Predictors of cancer-related fatigue in women with breast cancer before, during, and after adjuvant therapy. Cancer Nurs. 2008;31(2):134-44. doi: 10.1097/01.NCC.0000305704.84164.54.

  36. Xu J, Yin Z, Cao S, Gao W, Liu L, Yin Y, et al. Systematic review and meta-analysis on the association between IL-1β polymorphisms and cancer risk. PLoS One. 2013;8(5):e63654.doi: 10.1371/journal.pone.0063654. 

  37. Bastami S, Norling C, Trinks C, Holmlund B, Walz TM, Ahlner J, Uppugunduri S. Inhibitory effect of opiates on LPS mediated release of TNF and IL-8. Acta Oncol. 2013;52(5): 1022-33.

  38. Dahl AA, Nesvold IL, Reinertsen KV, Fossa SD. Arm/shoulder problems and insomnia symptoms in breast cancer survivors: cross-sectional, controlled and longitudinal observations. Sleep Med. 2011;12(6): 584-90. doi: 10.1016/j.sleep.2011.01.011.

  39. Mc Cann B, Miaskowski C, Koetters T, Baggott C, West C, Levine JD, et al. Associations between pro- and anti-inflammatory cytokine genes and breast pain in women prior to breast cancer surgery. J Pain. 2012;13(5):425-37.doi:10.1016/j.jpain.2011.02.358.

  40. Barratt DT, Klepstad P, Dale O, Kaasa S, Somogyi AA. Innate immune signalling genetics of pain, cognitive dysfunction and sickness symptoms in cancer pain patients treated with transdermal fentanyl. PLoS One. 2015; 10(9): 1-13. doi:10.1371/journal.pone.0137179

  41. Sakamoto K, Takeda S, Kanekiyo S, Nishiyama M, Kitahara M, Ueno T, et al.. Association of tumor necrosis factor-α polymorphism with chemotherapy-induced oral mucositis in patients with esophageal cancer. Mol Clin Oncol. 2017;6(1):125-129.  doi: 10.3892/mco.2016.1081.

  42. Liu X, Wang Z, Yu J, Lei G, Wang S. Three polymorphisms in interleukin-1beta gene and risk for breast cancer: a meta-analysis. Breast Cancer Res Treat. 2010; 124(3):821-5. doi: 10.1007/s10549-010-0910-3.

  43. Ransohoff RM. Chemokines and chemokine receptors: standing at the crossroads of immunobiology and neurobiology. Immunity. 2009;31(5):711-21. doi: 10.1016/j.immuni.2009.09.010.

  44. Nedoszytko B, Olszewska B, Roszkiewicz J, Glen J, Zabłotna M, Ługowska-Umer H, et al. The role of polymorphism of interleukin-2, -10, -13 and TNF-α genes in cutaneous T-cell lymphoma pathogenesis. Postepy Dermatol Alergol. 2016;33(6):429-434. doi: 10.5114/ada.2016.63881.

  45. Li Y, Ou C, Shu H, Zhao H, Zhu B. The ERCC1-4533/8092, TNF-α 238/308 polymorphisms and the risk of hepatocellular carcinoma in Guangxi Zhuang populations of China: Case-control study. Medicine (Baltimore). 2016;95(44):e5217.

  46. Gutiérrez-Hurtado IA, Puebla-Pérez AM, Delgado-SaucedoJI, Figuera LE, Zúñiga-González GM, Gomez-Mariscal K, et al. Association between TNF-α -308 G>A and -238 G>A gene polymorphisms and TNF-α serum levels in Mexican colorectal cancer patients. Genet Mol Res. 2016; 15(2). doi: 10.4238/gmr.15028199.

  47. Luo Y, Ye Z, LiK, ChenR, Li S, Pang J. Associations between polymorphisms in the IL-4 and IL-4 receptor genes and urinary carcinomas: a meta-analysis. Int J Clin Exp Med. 2015; 8(1):1227–33. eCollection 2015.

  48. Burada F, Dumitrescu T, Nicoli R, Ciurea ME, Angelescu C, Mixich F, Ioana M. IL-1RN +2018T>C polymorphism is correlated with colorectal cancer. Mol Biol Rep. 2013;40(4):2851-7. doi: 10.1007/s11033-012-2300-x.

  49. Sáenz López P, Vázquez Alonso F, Romero JM, Carretero R, Tallada Buñuel M, Ruiz Cabello F, Cózar Olmo JM. [Polymorphisms in inflammatory response genes in metastatic renal cance]r. Actas Urol Esp. 2009;33(5):474-81. [Article in Spanish]

  50. Bapat AA, Hostetter G, Von Hoff DD, Han H. Perineural invasion and associated pain in pancreatic cancer. Nat Rev Cancer. 2011;11(10):695–707. doi: 10.1038/nrc3131.

  51. Reyes-Gibby CC, Wang J, Spitz M, Wu X, Yennurajalingam S, Shete S. Genetic variations in Interleukin-8 and Interleukin-10 are associated with pain, depressed mood, and fatigue in lung cancer patients. J Pain Symptom Manage. 2013;46(2):161-72. doi: 10.1016/j.jpainsymman.2012.07.019.

  52. Ando K, Takahashi F, Motojima S, Nakashima K, Kaneko N, Hoshi K, Takahashi K. Possible role for tocilizumab, an anti-interleukin-6 receptor antibody, in treating cancer cachexia. J Clin Oncol. 2013;31(6):e69–72.doi: 10.1200/JCO.2012.44.2020


The fully formatted PDF version is available.

Download Article

International Journal of Biomedicine. 2017;7(4):277-281. ©2017 International Medical Research and Development Corporation. All rights reserved.